Neumora Therapeutics (NMRA) director granted 80,000 options at $1.86

Rhea-AI Filing Summary

Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date, and expire on May 26, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Piacquad David

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 80,000 options Exercise price: $1.86 per share Underlying shares: 80,000 shares +3 more

6 metrics

Option grant size 80,000 options Stock Option (Right to Buy) awarded to director

Exercise price $1.86 per share Conversion or exercise price of options

Underlying shares 80,000 shares Common Stock underlying the options

Total options after grant 80,000 options Total derivative securities following transaction

Expiration date May 26, 2036 Option expiration date

Vesting reference date May 27, 2026 One-year anniversary used in vesting schedule

Key Terms

Stock Option (Right to Buy), Common Stock, vest, Annual Meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest financial

"100% of the shares subject to the option vest on the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Annual Meeting financial

"immediately prior to the next Annual Meeting following May 27, 2026"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piacquad David

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.86	05/27/2026		A		80,000		(1)	05/26/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

	/s/ Michael Milligan, as Attorney-in-Fact for David Piacquad	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neumora Therapeutics (NMRA) report for David Piacquad?

Neumora Therapeutics reported that director David Piacquad received a grant of 80,000 stock options. These options give him the right to buy Neumora Common Stock at a fixed exercise price of $1.86 per share if they vest and are exercised.

What are the key terms of David Piacquad’s 80,000 Neumora (NMRA) stock options?

The grant covers 80,000 options to purchase Neumora Common Stock at an exercise price of $1.86 per share. The options expire on May 26, 2036, providing a long-term window for potential exercise if vesting conditions are satisfied.

When do David Piacquad’s Neumora (NMRA) stock options vest?

All 80,000 options vest 100% on the earlier of two dates. Vesting occurs on the one-year anniversary of May 27, 2026 or immediately before the next Neumora Annual Meeting following May 27, 2026, whichever happens first under the award terms.

Does the Form 4 for Neumora (NMRA) show a stock purchase or sale by David Piacquad?

The Form 4 shows an option grant, not an open‑market stock purchase or sale. It reports a compensation-related acquisition of 80,000 stock options with an exercise price of $1.86 per share and no shares bought or sold in the market.

How many Neumora (NMRA) derivative securities does David Piacquad hold after this transaction?

Following the transaction, David Piacquad holds 80,000 stock options as reported. These options are derivative securities tied to Neumora Common Stock, giving him the right to purchase 80,000 underlying shares at $1.86 per share if exercised after vesting.